• 沒有找到結果。

Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw Oral Science International

N/A
N/A
Protected

Academic year: 2022

Share "Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw Oral Science International"

Copied!
8
0
0

加載中.... (立即查看全文)

全文

(1)

ContentslistsavailableatSciVerseScienceDirect

Oral Science International

j ou rna l h o m e p a g e :w w w . e l s e v i e r . c o m / l o c a t e / o s i

Review

Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw

Tetsuro Ikebe

DepartmentofOralandMaxillofacialSurgery,FukuokaDentalCollege,2-15-1Tamura,Sawara-ku,Fukuoka814-0193,Japan

a r t i c l e i n f o

Articlehistory:

Received27February2012

Receivedinrevisedform21March2012 Accepted22March2012

Keywords:

Osteonecrosis Bisphosphonate Osteoclast Mevalonate

a b s t r a c t

Sincethefirstarticleaboutbisphosphonate-relatedosteonecrosisofthejaw(BRONJ)waspublishedin 2003,clinicalandbasicresearchforBRONJhascontinuedworldwidetounderstandthisnoveldisease.

Severalorganizationshaveproposedthedefinition,diagnosticcriteria,riskfactors,andtreatmentstrat- egyforBRONJ.Recently,somenewdrugsusedforcancerpatientssuchasbevacizumabandsunitinib havealsobeenreportedtobeinvolvedinosteonecrosisofthejaw(ONJ).BecauseONJappearstobeini- tiallyderivedfromosteoclastinhibition,anewcategoryofdiseasesnamedas“drug-relatedosteoclastic diseaseofthejaw”maybeassumed.ConsideringtheaccumulatedknowledgerelatedtoBRONJ,including osteoclastbiology,bisphosphonatepharmacology,animalexperiments,andclinicopathologicalfindings, aperspectiveofBRONJfromthepathophysiologicalviewpointisproposedinthisreview.

© 2012 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.

Contents

1. Introduction... 2

2. IncidenceofandriskfactorsforBRONJ. . . ... 2

2.1. Incidence... 2

2.2. Toothextraction. . . ... 2

2.3. Glucocorticoids... 2

3. DiagnosticcriteriaandstageclassificationofBRONJ. . . ... 2

3.1. Criteriaandstage... 2

3.2. Stage0. . . ... 3

4. Relationshipbetweenstage0andsuppurativeosteomyelitisofthejaw... 3

5. Mechanismofnitrogen-containingBPactions. . . ... 4

6. OthertargetcellsofBP... 4

6.1. Osteoblasts... 4

6.2. Osteocytes... 4

6.3. Vascularendothelialcells... 4

6.4. Keratinocytes... 5

6.5. Macrophages/monocytes... 5

7. WhydoesBRONJoccurinthejaws?... 5

7.1. Boneturnoverrate... 5

7.2. Vulnerabilityofthejawtobacterialinfection... 5

8. ConfusedeffectofnBPonosteomyelitisofthejaw... 5

9. PathophysiologicalmechanismofBRONJ... 5

10. TreatmentofBRONJ... 6

10.1. Drugholiday... 6

10.2. Hyperbaricoxygen... 6

10.3. Teriparatide(recombinanthumanparathyroidhormone1–34)... 6

10.4. Prospectivetherapy... 6

11. Drug-relatedosteoclasticdiseaseofthejaw... 7

References... 7

∗ Correspondingauthor.Tel.:+81928010411;fax:+81928011288.

E-mailaddress:ikb@college.fdcnet.ac.jp

1348-8643/$seefrontmatter © 2012 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.

http://dx.doi.org/10.1016/S1348-8643(12)00045-6

(2)

1. Introduction

The number of the patients with bisphosphonate-related osteonecrosisofthejaw(BRONJ)hasincreasedyearbyyearsince Marxfirstreportedcasesofosteonecrosisofthejaw(ONJ)occur- ringinpatientswithmultiplemyelomatreatedwithintravenously administeredbisphosphonatein2003[1].Thediseaseconceptof BRONJseemstobeestablishednowsincemanyarticlesandreviews aboutBRONJhavebeenpublished.

Bisphosphonate(BP)wasoriginallydevelopedasadrugtotreat boneresorbingdiseasessuchasmultiplemyelomaandbonemetas- tasis,whosetypicaloriginsarebreastcancerandprostatecancer,as wellastumor-relatedhypercalcemia,andthenusedforthepatients withosteoporosistopreventtheirpathologicalfracture.InJapan, approximately3millionpatientshavereceivedBPtherapy.Aspe- cifictarget cellofBPisosteoclast whichplaysa centralrole in physiologicalandpathologicalboneresorption.

Since BP possesses a pyrophosphate-like structure, whose hydroxylgroupconfersastrongaffinitytothehydroxyapatite,80%

ofBPadministeredintravenouslyororallydepositstothebones.

ThehalflifeofBPinhumans,whichispoorlymetabolizedbybio- logicalenzymes,isthoughttobeabout10years,andthusBPmay beenrichedinthebones,towhereosteoclasts,whichdifferentiate frombonemarrowstemcells,migrateandadheretofunction.That iswhyBPwasexpectedtoworkselectivelyonosteoclastswith- outadverseeffects.Nitrogen-containingBP(nBP)hasmorepotent abilitytoinhibitmineraldissolutionandhigherpotencytoinduce BRONJthanearlyBPwithoutnitrogen-containingside-chain[2].In thisreview,“BP”occasionallyindicatesbothnBPandearlyBP.

LikeBP,denosumab,whichisanti-humanRANKligand(RANKL) monoclonalantibodyanddevelopedtoinhibitosteoclastsforthe treatment of bone-resorbing diseases, is also suspected to be involvedintheoccurrenceofONJthatissimilartoBRONJ[3,4].The symptomsseeninchronicosteomyelitisofthejawoccurringinthe patientswithosteopetrosis,inwhichosteoclastfunctionsareinhib- itedbyageneticmutation,alsoseemtobesimilartothoseofBRONJ.

Sincetheselesionsappeartobederivedfromosteoclastinhibition, wecouldclassifythemintoanewcategoryofdiseasespresumably namedas“drug-relatedosteoclasticdiseaseofthejaw”.Thisideais basedontheconceptthatthe“osteoclastisaself-defenseregulator ofthejaw.”Thedefensemechanismofthejawshouldbeimpaired inthelackofosteoclasts,whichislikentothatwebecomesus- ceptibletoinfectionwhenourimmunecellsareinhibited.Inthis review,hence,theclinicalaswellaspathophysiologicalaspectsof BRONJwillbediscussedaccordingtothisconcept.

2. IncidenceofandriskfactorsforBRONJ 2.1. Incidence

TheincidenceofBRONJintheearlyUSAreportwas0.8–12%

withintravenousBPand 0.7/100,000(0.0007%)person-yearsof exposurewithoralBP[5].InEurope,theincidencewas95/100,000 (0.095%)person-yearsofexposurewithintravenousadministra- tionand1/100,000(0.001%)person-yearsof exposurewithoral administration [6]. BRONJ occurred in 1.15% of intravenously administered patients and in 0.04% of the orally administered patientsinAustralia[7].AnotherreportfromtheUSAindicatedthat theincidenceofBRONJwas0.1%withoralBPadministration[8].

Takentogether,thesereportssuggestthattheincidenceofBRONJ withoralBPis0.01–0.1%.

MostofthepatientstakingoralBPhaveosteoporosis.Approx- imately20%ofthe10millionosteoporosispatientsinJapanare thoughttobetreatedwithmedicationincludingBPs.Astheelderly populationincreases,thenumberofosteoporosispatientstaking

oralBPwillincreaseandtheperiodforBPadministrationwillpro- long,whichwillresultinanincreasedincidenceofBRONJ.Actually, anationwideretrospectivecohortstudywithaquestionnaireon BRONJinJapan,whichwasundertakenbytheJapaneseSocietyof OralandMaxillofacialSurgeons,demonstratedthat263casesof BRONJoccurredintheentryhospitalsfrom2006to2008,and39.5%

ofthemwerepatientstakingoralBPs[9].

2.2. Toothextraction

Among various risk factors, including glucocorticoids (GCs), anti-cancer drugs, alcohol, smoking,and malnutrition,to make patientssusceptible toBRONJ,toothextractionand othersurgi- calprocedurestothejawsaremostproblematictodentistsand oralandmaxillofacialsurgeons.Toothextractionraisedtheinci- dence of BRONJ about 8-fold, from 0.04% to 0.34% in the oral BP-administeredpatientsandfrom1.15%to9.1%intheintravenous BP-administeredpatientsinAustralia[7].BRONJ occurredin6%

in66patientsorallytakingaledronateaftertoothextraction[10].

Toothextractionwasrelatedto77%ofBRONJcasesoccurringinthe patientsintowhomBPwereadministeredintravenously[11].Sur- gicaldamagetothejaw,especiallyalveolarbone,islikelytobethe mostpotenttriggertoBRONJwhiletheimmunosuppressiveagents suchasGCsandanti-cancerdrugs,couldlowerthethresholdforits occurrence.

Without any risk factors, BRONJ is known to occur spon- taneously. The lingual side of the alveolus in mandible is a predisposedsiteforspontaneousBRONJ,whichisthoughttobe triggeredbyaninjuryonthemucosa.Likewise,bonyprominence seeninpalataltorusandmandibulartorusisalsosusceptibleto BRONJ.

2.3. Glucocorticoids

The use of GCs with BP is known to raise the risk for BRONJbecauseGCssuppresstheactivitiesofinflammatorycells and immune cells to make thepatients immunocompromized.

SinceGCsnot onlyactivate theosteoclasts,butalsoinhibitthe osteoblasts,thelong-termuseofGCsinduceosteoporosis.Thatis whypatientsundergoingGCtherapyarealsoadministeredBPto preventosteoporosis.Rheumatoidarthritis(RA)isatypicaldisease treatedbothwithBPandGCs.SomeofthepatientswithRAarealso treatedwithmethotrexate(MTX)togetherwithBPandGC.MTXisa folicacidantagonistandusedasananti-cancerdrugaswellasanti- rheumaticdrugbyinhibitingtheinflammatorycellsanddecreasing variouscytokineproductions,whichislikelytoincreasetheriskof BRONJ.RApatientsshouldbepaidspecialattentionforpreventing BRONJ.

3. DiagnosticcriteriaandstageclassificationofBRONJ 3.1. Criteriaandstage

In2007,criteriatodiagnoseBRONJwereprovidedinaposition paperbytheAmericanAssociationofOralandMaxillofacialSur- geonsasfollows:(1)currentorprevioustreatmentwithaBP;(2) exposedboneinthemaxillofacialregionthathaspersistedformore than8weeks;and(3)nohistoryofradiationtherapytothejaws[5].

Althoughanexposureofnecroticbone,sequester,inthejawisthe mostprominentcharacteristicofBRONJ,itisoccasionallyobserved inchronicsuppurativeosteomyelitisofthejaw.Thatseemstobea reasonwhythecriteriaincludethesecondpoint.Thecriterion(3) istoexcludethepossibilityofosteoradionecrosisofthejaw.

Thepositionpaperin2007alsoproposedastagingclassifica- tionofBRONJ,stage1,stage2,andstage3.Stage1showsonlyan exposureofthebonewithoutinfectioussigns.Stage2includesnot

(3)

Table1

Comparisonofthelevelbetweenjawinflammationandbisphosphonate-related osteonecrosisofthejaw(BRONJ).

Category Levelofthelesion

Alveolus Jawbody

Ostitis Alveolarostitis Periostitis

Periodontitis

Abscess Gingivalabscess Subperiostealabscess

Alveolarabscess

BRONJ Stage2 Stage3

onlyaboneexposure,butalsoinflammatorysymptomsbybacte- rialinfectionsuchaspainandswelling.Theextentofthelesion instage2islimitedinthealveolarbone.Whenthelesionextends tothejawitselfbeyondthealveolarlevel,then,itwillbeclassi- fiedtostage3,wherethebonenecrosisorosteolysismayextend totheinferiorborderofmandiblewithorwithoutextraoralfis- tulaandpathologicalfracture.Thedifferencebetweenstage2and stage3willbesimilartothatbetweenperiodontitisandperiostitis, dependingontheaffectedarea(Table1).

3.2. Stage0

AllthestagesofBRONJrequireanexposedboneasadefinition.

However,itisknownthattherehavebeenpatientstakingoralBP whohavenoboneexposureinthejaw,butsufferedfromsomenon- specificandrefractorysymptomssuchasdiffusealveolarswelling, gingivalredness,orinternaldentalfistulawhoseoriginsarenot identified.Thesesymptomshaveoccasionallysubsidedafterthe discontinuationofBPtherapy.TheAmericanAssociationofOral andMaxillofacialSurgeonspositionpaperin2009addedastage 0intotheBRONJstagingforthecaseswithnoclinicalevidence ofnecroticbone,butnonspecificclinicalfindingsandsymptoms [12].Fig.1showsaplausibleexplanationaboutthedevelopment ofstage0.Instage0,anopenalveolarsocketmaypersistaftertooth extraction,wherethesurfaceofthesocketisconcealedwithgran- ulationtissues,butthemostpartofthebaresocketisleftbehind withabonysurface,presumablybecausethethickenedlaminadura [13],whichcannotberesorbedbyBP,maypreventtheinflamma- torycellsfrominfiltrating,impairthewoundhealingprocesses,and allowtheinfectiontopersist(Fig.1).

4. Relationshipbetweenstage0andsuppurative osteomyelitisofthejaw

Dentists or oral and maxillofacial surgeons may diagnose the patients with stage 0 simply as suppurative periostitis or osteomyelitisofthejaw,beingunawareoftheirBPadministration.

Ifstage0lesionisaprecursorofBRONJ,bacterialinfectionmayplay acriticalroleintheinitiationofBRONJ.

Kosetal.[14]reportedthatwhenpatientswithosteomyelitis of the jaws were divided into two groups, the ones undergo- ingBPtreatmentandtheotherstaking noBP, Actinomyceswas significantlydetectedontheexposed necroticbonesin theBP- administeredpatients,suggestingtheinvolvementofActinomyces in BRONJ. Ganguli et al.[15] suggest theaffinity of bacteria to BP by showing increased adhesion of Staphylococcus aureus to hydroxyapatiteinjointprosthesescoatedwithpamidronate.On theotherhand,Hansenetal.[16]alsodetectedActinomycesinthe necroticbonesofBRONJaswellasosteoradionecrosisinanequally highfrequency.BothnecroticbonesfromBRONJandsuppurative osteomyelitisofthejawswerefoundtobecoveredwiththebac- terialbiofilms,but,Actinomycespredominatedinthebiofilmfrom suppurativeosteomyelitiswhilethebiofilmfromBRONJincluded morediversebacterialorganismsinadditiontofungalorganisms notobservedinsuppurativeosteomyelitis[17].Althoughitremains unknownwhetherbacterialinfectionsincludingActinomycesoccur primarilyorsecondarilyintheBRONJprocess,infectionislikelyto worsenthesymptomsofBRONJ.Thus, BRONJstage0shouldbe initiallytreatedwithantibacterialmouthrinseandantibiotics.

As mentioned below, BP inhibits the growth of vascular endothelialcellsandimpairstheangiogenesisinboneandperios- teum.Thedecreaseinbloodsupplymayleadtoavascularnecrosis ofthejawinBRONJ,whichislikeosteoradionecrosisofthejaws.

But,itisunlikelythatavascularandasepticnecrosisofthebonesisa primarycauseofBRONJsincesomeinfectiouslesionssuchasgingi- valabscessoftenprecedethedevelopmentofBRONJinmanycases [18],andstage0ofBRONJusuallyshowssomeinfectionsigns.Saia etal.[19]reportedthatamong60casesoftoothextractionunder BPtreatment,BRONJoccurredin3caseswithin3months,suggest- ingthatsuppurativeosteomyelitismightbethemostinfluential riskfactortobringoutBRONJ.

RegardlessofwhetherbacterialinfectioncausesBRONJornot, itisimportanttofindoutthecasesofstage0asearlyaspossible andpreventthemfromprogressingtothelaterstages.Hutchinson etal.foundtheradiographicfeatureswithpanoramicradiography andcomputedtomography(CT),includingdiffuseosteosclerosis,

Fig.1.WhathappensinthejawofStage0?Thickenedlaminadurawillpreventwhitebloodcellsfrominfiltratingandgranulationtissuefromforminginthesocket,resulting indelayedwoundhealingandpersistentinfection.

(4)

Fig.2. Bisphosphonate (BP) targetingthe mevalonate pathway. FPP,farnesyl diphosphate;PP,pyrophosphate.

thickenedlaminadura,prominenceoftheinferioralveolarcanal, andcorticaldisruption,in10casesamong30patientswithstage0 [20].Inmyopinion,hence,CTorconebeamCTseemstobeuseful todetecttheseinitialchangesinthebonesfortheearlydiagnosis ofstage0.

5. Mechanismofnitrogen-containingBPactions

ThemoleculartargetofnBPisafarnesyldiphosphatesynthase (FPPsynthase)inosteoclasts[2,21,22].Atfirst,nBPwassupposed toinhibitthemineraldissolutionbyitsbindingtomineralcom- ponentsoutsideosteoclasts,butnowitisknownthatnBPenters intotheosteoclaststoinhibittheactivityofFPPsynthasewhichis anenzymeinvolvedinmevalonatepathwayofosteoclasts(Fig.2).

ThiseffectofnBPwasfoundintheresearchforanagenttolower thelevelofserumcholesterolwhichissynthesizedthroughmeval- onatepathway[2].FPPsynthaseisanenzymetoconvertgeranyl diphosphatetofarnesyldiphosphate,whichisinturnconvertedto geranylgeranyldiphosphate.Geranylgeranyldiphosphateactivates thesmallGTPases,suchasRab,Rac,Ras,andRho,throughtheiriso- prenylationandgeranylgeranylation.SmallGTPasesthenregulate thecytoskeletalarrangement,vesiculartrafficking,andmembrane rufflingwhichareinvolvedintheprocessesofboneresorptionby osteoclasts,includingtheirmigrationtobones,adhesiononbone surfaceandtransportationofbone-resorbingenzymestotheruf- fledborder.Therefore,theinhibitionofFPPsynthasewithnBPcan preventosteoclastsfromdestructingthebones(Fig.2).

TheremaybeevidencetoshowthatnBPdisturbsthecytoskele- talregulation. Weinstein et al. observed theosteoclasts in the bone-biopsyspecimensofiliacboneobtainedfromhealthypost- menopausalwomen receiving3-year oral alendronate therapy, comparedwiththe placebo-controlledonesin a doubled-blind, randomizedtrial[23].Intheory,itwasexpectedthattherewould befewosteoclastsinthebonesfromthepatientstakingnBP.Sur- prisingly,however,thenumberoftheabnormalosteoclasts,which weregiant,hypernucleated(with20–40 nuclei),detached from bone surface, increased as the cumulative dose of alendronate increased.Ofthesegiantosteoclasts,20–37%wereapoptotic.They suggestthatnBPprotractstheapoptosisofosteoclasts,wherecell fusioncontinuestogeneratethedistinctivemorphologysuchas giantismandhypernucleation.Thesefeaturesmaybeattributedto nBP-mediatedlossofsmallGTPase.

Suchanincreaseinthenumberofgiant,hypernucleatedosteo- clastsisalsoobservedinthebonesfrompatientswithSchönberg diseaseorautosomaldominantosteopetrosistypeII,inwhichthe abilityofosteoclaststodecayboneisimpairedbecauseofthemuta- tionsinCLCN7gene encodinga chloridechannel[24].nBPmay inhibitthefunctionofCLCN7[25].Hansenetal.[16]alsofound manyosteoclastsinthenecroticbonesfromtheBRONJpatients

administeredwithpamidronateorzoledronate.Thesedatasug- gestthatnBPbringsaboutthefunctionaldisorder,ratherthanthe depletion,ofosteoclasts.

6. OthertargetcellsofBP

Althoughosteoclastshavebeenthoughttobeaspecifictarget ofnBP,itisdifficulttoattributetheoccurrenceofexposedbone necrosisonlytoosteoclastdisorder.Someothercellsarethought totakepartinestablishingBRONJ.

6.1. Osteoblasts

Osteoclasts are known to indirectly assist bone formation, whereosteoclasticboneresorptioncanreleasesomegrowthfactors buriedinthebone,whichstimulateosteoblaststomakebones[26].

Thecooperationofosteoclastswithosteoblasts,which iscalled

“coupling”,isthoughttobeessentialforboneturnover.Thus,the lossofosteoclastsis likelytoimpairtheactivityofosteoblasts, resulting in the bone turnover arrest to osteonecrosis. On the otherhand,thedirecteffectsofnBPonosteoblastshavealsobeen investigated.Zoledronateinhibitedthegrowthandviabilityofcul- turedosteoblasts[27,28],whilepamidronateandzoledronatewere reportedtoinhibitthecellgrowth,butincreasetheboneformation ofimmortalizedfetalosteoblasts[29].Thedamagetoosteoblasts maybeassociatedwiththeoccurrenceofBRONJ,whichhypoth- esismaybesupportedbythereportthat parathyroidhormone mightimprovetheBRONJbystimulatingosteoblasts,asmentioned below.

6.2. Osteocytes

AllenandBurr[30]examinedthebonematrixinthemandible frombeagledogs treatedwithclinically relevantdoses ofdaily oral alendronate for 3 years and found significant amounts of necrotic bone matrix in approximately25% ofnBP-treated ani- mals,whichwerepredominantlypresentinthealveolarportionof themandible.Thenon-viablebonematrixshowedemptylacunae withoutosteocytes.Ithasbeenreportedthatfluorescentlylabeled risedronateinjectedintravenouslyintomicewasobservedaround thelacunae[31].Becauseosteocytesarethemostabundantbone cellsandformanintricatecommunicationnetworkthroughoutthe bonematrix,whereosteocytesarethoughttoprovideasignalto osteoclaststocleanupthenecroticbones,thelossofosteocytes mayplayaroleinthepathophysiologyofBRONJ[32].Itislikelythat themicronecrosisofthebonemayaccumulateinlargeamounts becauseofthelackofosteocyte–osteoclastcommunication[33,34].

6.3. Vascularendothelialcells

ItisassumedthatBPinhibitsboneangiogenesisbysuppress- ingthegrowthofvascularendothelialcellstoresultinavascular necrosisofthebone.ThereareanumberofreportstoshowthatnBP directlyinhibitsangiogenesisinvitroorinvivo[35,36,28]although thestudiesontheeffectsof nBPonangiogenesisinbone mar- rowandperiosteumofthejawremaintobedone[37].nBPmay alsoexertindirecteffectsonthesuppressionofboneangiogene- sissinceosteoclastsmayberequiredtomakevesselspassthrough bonematrix[38].ThisimportanceofnBP-mediatedinhibitionof angiogenesisinthejawcouldbesupportedbythereportsthatthe administrationofzoledronatereducedtheserumlevelsofvascular endothelialgrowthfactor(VEGF)inpatientswithbonemetasta- sis[39]andthatbevacizumab,ananti-VEGFantibody,mayinduce osteonecrosisofthejaw[40].

(5)

6.4. Keratinocytes

nBPisreportedtoinhibitthegrowthofculturedkeratinocytes [41].nBPdecreasedthenumberofp63-positivekeratinocytepro- genitorcellsandpreventedthegingivalfibroblastsfromproducing keratinocyte growth factor (KGF) [42,43]. It is presumed that inflammationinthejaws,i.e.toothextraction,releasesthenBP buriedinthebones,whichinturninhibitsthekeratinocytegrowth toworsen theexposureofbones,especiallyinpatientswithan ulceroraninjuryformedonthemucosabyunsuitabledentures.

ThemucosaldamagewithnBPisdemonstratedinacasethatthe contactofnBPonmucosainducedstomatitisinpatientswhohad thehabittoholdthealendronatetabletsinthemouthforawhile beforeswallowingthem[44,45].

6.5. Macrophages/monocytes

Sinceosteoclastsdifferentiatefrommacrophage/monocytelin- eage,itisplausiblethatnBPinhibitstheactivityofmacrophages.

Actually,nBPinhibitedtheproductionofcytokinesinmacrophages and monocytes [31]. The differentiation of dendritic cells, a macrophagelineage, wasinterferedwithby nBP[46,47].These macrophages/monocytesplayanimportantroleintheself-defense systemofimmunityasantigen-presentingcells. Thus,nBPmay suppresstheimmunologicalreactionstomakebonessusceptible tobacterialinfection.Inthisrespect,thereasonwhyGCisariskfac- torforBRONJisthoughttobeattributedtoitsimmunosuppressive action[48,49].Inaddition,itislikelythatnBPinhibitsthediffer- entiationfrommacrophage/monocytetoosteoclast.Kimachietal.

[50]reportedthatzoledronateinhibitedthetumornecrosisfactor-

␣-induceddifferentiationofamurinemacrophage/monocytecell line,Raw264.7tomatureosteoclasts.

7. WhydoesBRONJoccurinthejaws?

It isthoughtthat jawis themostpredisposedtoBP-related osteonecrosisbecause(1)theturnoverrateofjaws,especiallyalve- olarbones,issorapidand(2)jawshaveteethandgumthatmay becomeaneasyentranceforbacterialinfection[51].

7.1. Boneturnoverrate

Theremodelingratesofthecorticalboneinthejaware10–20 timeshigherthaninthecortexofiliaccrestinhumans[52,53].The levelofintracorticalboneremodelinginthemandiblewasfound tobemorethan10timeshigherthaninthetibialcortexindogs, especially,thealveolarportionofthemandiblehavingmorethan 8timeshigherrateofturnoverthanintheotherportionsofthe mandible[37].Incontrast,somearticlesshowthattheturnover ofthejawisnotthehighestamongthebones.HujaandBeck[54]

reportedthattheboneformationrateofthefemurishigherthan thatofthemandibleandmaxillaindogs.Inathymicrats,theuptake offluorescentlylabeledpamidronatetothebonesandtherelease ofitperunitcalciumwerelowerintheoralbonesthanintheaxial bones[55].Apartfromthecontroversy,bonedamagesuchassur- gicalinterventionandinfectionmayacceleratetheturnoverrateof thejaw.

Whenfluorescentpamidronatewasinjectedintravenouslyinto mice,90%ofthefluorescentsignallocalizedtobonewithin2–6hof injection,wheremoresignalsweredetectedandretainedlongerin themandibleratherthaninthefemur[56].Moreover,fluorescent pamidronatewasfoundtobedepositedinthealveolarboneand bonesurroundingtheperiodontalligamentandmolarroots[56].

Takentogether,alveolarboneofthemandibleismostsusceptible

tothenBPeffectsbecauseofrapidturnoverrateandhighaffinity tonBP.

7.2. Vulnerabilityofthejawtobacterialinfection

Amongallthebones,jawseemstobethemostliabletobacte- rialinfectionsincemucosacoveringthealveolarboneisverythin andvulnerable,and teetheasilybecomeapathwayforbacteria fromtheoutsideintothebone.Althoughitiscertainthatbacterial infectionmakesBRONJworse,itremainstobedeterminedwhether bacterialinfectionprecedesosteonecrosisofthejaw.Aghalooetal.

[57]foundthatthenecrosisofthealveolarbonesdevelopedinthe rats,whichunderwent theplacementofa wireligaturearound thecrownofmaxillarymolarinaperiodontaldiseasemodel,after intraperitonealinjectionwithzoledronate.Thenecroticboneswere notexposedintheseratswhereasthecontrolanimalsshowedthe resorptionofalveolarbone,butnotanyosteonecrosis.Theresults imply thatperiodontitis, whichis presumablyinfection-related, cantriggertheosteonecrosis.

Whenperiodontitisoccurs,inflammatorycellsarerecruitedto thesitestoeliminatethecausativepathogens.However,theblock- ade of boneresorption withBPmaymake it difficultfor these cellstoaccesstothepathogens,allowingtheinfectiontopersist.

Theresultingaccumulationofbacterialtoxinsandinflammation- generated superoxides will promote the bone necrosis. Thus, bacterialinfectionislikelytobeinvolvedintheformationofBRONJ.

From theseassumptions, it seemsto be reasonable totreat BRONJwiththoroughlocalrinseandantibioticadministrationasa firststeptocontroltheinfection.

8. ConfusedeffectofnBPonosteomyelitisofthejaw

Ontheotherhand,pamidronateisusedtotreatpatientswith chronicnon-bacterialosteomyelitis(CNO),includingchronicrecur- rent multifocal osteomyelitis (CRMO), SAPHO (synovitis, acne, pustulosis,hyperostosis, and osteitis),and juvenilediffuse scle- rosingosteomyelitis(DSO),whichoccasionallyoccurinthejaws [58–61]. Although the causative mechanism of CNO remains unknown,theeffectivenessofBPonCNOmayrathersupportthe hypothesisthatbacterialinfectionisinvolvedintheinitiationof BRONJ.BPcancurenon-bacterialosteomyelitiswhileBPworsens suppurativeosteomyelitistoBRONJ.

Whendentalsurgicalprocedureswereappliedto22patients with osteogenesis imperfecta who underwent BP therapy, no BRONJcaseswereobserved[62].Itremainsunknownwhytheinci- denceofBRONJissolowwhenBPtherapyisappliedtoosteogenesis imperfectaandCNO.

9. PathophysiologicalmechanismofBRONJ

Based onourknowledge assummarized above,theputative mechanism of BRONJ formation is summarized in Fig. 3. After administration,nBPsdepositandaccumulateinthealveolarbone, whichhaveahigherturnoverrate.Duringaphysiologicalremod- eling of the bone, osteocytes are exposed to the buried nBPs and damaged, leading to the micronecrosis of the bones. The amountsofthenecroticbonesgraduallyincreasebecauseosteo- clastscannotdegradethenecroticbones.Whentoothextraction is performed, then, the inflammatory cytokines are produced in theperiodontal tissues,which exert theserial inflammatory reactions,wherethetissue-degradingproteasesmaybeinvolved in the increased release of nBPs from the alveolar bones. The releasednBPsmayblockangiogenesisanddelaythemigrationof neutrophils,macrophages,andosteoclastprogenitorstothesite, inhibitingtheformationofgranulationtissues,whichareneeded

(6)

Fig.3. Hypothesisofpathophysiologyofbisphosphonate(BP)-relatedosteonecrosisofthejawdevelopment.

forwoundhealingandboneremodeling.Thepoorvascularityand sequestrationinperiodontaltissuesmakesthebacterialinfection persistbecausetherecruitmentofneutrophilsandlymphocytes areblocked.Thefistulaformationtodischargepusinsideboneis alsopreventedbecauseofthelackofosteoclasts.Thepersisting infectionpromotestheincreaseinosteonecrosiswhiletheuncou- plingbetweenosteoblastsandosteoclastscausesthesuppression ofboneturnover.ThereleasednBPsfinallyinhibittheproliferation ofmucosalkeratinocytes,leadingtotheexposureofnecroticbones.

10. TreatmentofBRONJ

ThestrategiesforthetreatmentofBRONJhavebeenproposedin thepositionpapersdependingonthestages[5,9,12].BRONJstage 3maybetreatedwithasurgicalremovalofthejawwhichcontains thenecrotic boneswhilea conservativetherapyisindicated for stage1orstage2.Oneofthebasicconservativetherapiesisalocal irrigationwithsalineortheuseoforalantimicrobialrinse.

10.1. Drugholiday

InthepatientstreatedwithoralBPtherapy,adrugholiday,dis- continuationofBPtherapy,seemstobeeffectivetorestorebone turnoverofthejawandsupportthetreatmentofBRONJ.Inthe positionpapers, the discontinuation ofBP is recommended for morethan3monthsbeforetoothextractionifthepatientshave receivedoralBPtherapyformorethan3years.Itisexpectedthat boneturnoverofthejawoncedisturbedwithBPwillberecovered duringa3-monthdrugholiday.Thisconceptissupportedbythe reportofMarxetal.[63],wheretheserumconcentrationsofCTX, whichisacross-linkingpeptideoftypeIcollagen,releasedfrom thebonesduringboneresorptionandutilizedasamarkerofbone turnover,weremeasuredinthepatientswithBRONJ.Theyfound thattheserumconcentrationsofCTXincreasedfrom72.4pg/ml to150pg/ml,whichisinthelevelforlowriskofBRONJ,withthe discontinuationofBPfor3–4months.Hence,a3-monthholiday fromBPmay restorebone turnoverof thejaw.Infact, Treister andWoo[64]reportedthatthemucosacompletelycoveredthe exposedboneinstage2ofBRONJ4monthsafterthediscontinu- ationofBPandlocalrinse.DiscontinuationoforalBPtherapyis thoughttobethefirststeptocareforpatientswithBRONJ.

ItremainscontroversialwhetherserumCTXconcentrationcan beusedasapredictivemarkerforBRONJ,becausethevaluesofCTX concentrationseemtovaryfromcasetocase[65,66].

10.2. Hyperbaricoxygen

Sincehyperbaricoxygen(HBO)isknowntobeeffectiveadjunc- tive therapy for the treatment of chronic osteomyelitis and osteoradionecrosisofthejaw,then,ithasalsobeenappliedtothe treatmentofBRONJ.TheefficacyofHBOinthetreatmentofBRONJ hasnotyetbeenelucidated,butmaybepromisingbecauseitis expectedtoimprovethehypoxiaconditioninthejawandgener- atereactiveoxygenspecies(ROS)tostimulatethedifferentiation andactivityofosteoclasts[67].

10.3. Teriparatide(recombinanthumanparathyroidhormone 1–34)

Recently, it hasbeen reported that BRONJ wasdramatically improvedwithteriparatidetherapy[68–70].Teriparatideconsists of1–34aminoacidsofrecombinanthumanparathyroidhormone (PTH)(afullPTHincludes84aminoacids),andhasbeenusedfor thetreatmentofGC-inducedosteoporosis.PTHplaysanessential roleintheregulationofcalciummetabolism.WhenPTHlevelsare continuouslyelevated,bonesareseverelydegradedtoincreasethe serumcalciumconcentrationbecauseofosteoclastactivation.In contrast,intermittentpulsatileadministrationofPTHstimulates thedifferentiationandfunctionofosteoblasts,ratherthanosteo- clasts,toleadtoanaboliceffectsonbone[71].Hence,intermittent subcutaneousinjectionofteriparatideonceadayisexpectedto promoteboneformation.InthetreatmentofBRONJ,teriparatide maycauseactivationofosteoblaststorestoretheboneturnover onceinhibitedwithnBP,andpromotetheproductionofreceptor activationofnuclearfactor-kBligand(RANKL)fromosteoblaststo reactivateosteoclasts.

10.4. Prospectivetherapy

Asmentionedabove,nBPsimpairosteoclaststhroughinhibiting FPPsynthaseinthemevalonatepathway(Fig.2).Ifadownstream moleculeoffarnesyldiphosphatewhosegenerationismediated

(7)

Fig.4.Aroleofosteoclastsinself-defenseofthejaw.Osteoclastsplayanimportantroleinexcludingbacteriafromtheinsideofjaw.BP,bisphosphonate.

Table2

Listofthedrugsrelatedtoosteonecrosisofthejaw.

Drugsrelatedtoosteonecrosisofthejaw Bisphosphonate

Glucocorticoid Bevacizumab Denosumab Sunitinib

withFPPsynthaseinthemevalonatepathwayissuppliedintothe nBP-treatedosteoclasts,theinhibitoryeffectsofnBPonosteoclasts wouldbecompensated.Kimachietal.[50]foundthattheaddition ofgeranylgeranyldiphosphate,whichisadownstream metabo- liteofFPPsynthase,dramaticallyrestoredthemotilityandRANK expressionoftheculturedosteoclastprecursorswhichwereonce inhibitedwithzoledronate,implyingthatgeranylgeranyldiphos- phateneutralizestheeffectofnBP.Suchanintermediatemetabolite inthemevalonatepathwayisexpectedtobecomeadrugtorevive theosteoclastsinthepatientswithBRONJ[72].

11. Drug-relatedosteoclasticdiseaseofthejaw

Recently,ithasbeensuspectedthatONJisinducednotonlyby nBP,butalsobythemolecule-targetingdrugs,whicharenewly developed,suchasdenosumab,anti-RANKLantibody,andbeva- cizumab, an anti-VEGF antibody [2,40,73]. The number of case reportsaboutONJoccurringincancerpatientstreatedwiththese new anti-cancer drugs appears to be increasing (Table 2).The incidenceof ONJwas0.3–0.4%inthe patientswithbreast can- cerundergoingbevacizumabtherapywhereastheadministration ofbevacizumab togetherwithnBP increasedtheONJincidence to0.9–2.4%[74].Thecombination ofnBP withsunitinib, which inhibitstyrosinekinaseinvolvedinvariousgrowthfactorreceptors totreatrenalcellcarcinoma,isreportedtoraisetheriskofBRONJ, wheresunitinib-inducedoralmucositisisthoughttotriggerthe occurrenceofBRONJ[75].

Accordingtorecentadvancesinmedicalscience,anumberof newdrugs have beendeveloped and appliedtopatients, espe- ciallythosewithcancer.Oursocietywillspeedupthissituation inthefuture.Ontheotherhand,themorenewdrugsaredevel- oped,themoreadverseeffectswillemerge.Newdrugsmayinduce newdiseasessuchasBRONJ.Itisplausiblethatthejawisthemost vulnerablesitetotheadverseeffectsofnewdrugsbecauseofits specialanatomicalcharacteristics.Furthermore,ajawiscomposed ofavarietyofcells,allofwhichshouldtakepartinthelifeofthejaw.

EvendamageonlytoosteoclastswithBPwilldisturbthenetwork ofeachcellthroughthejaw.Fromthisviewpoint,ourexperiences

aboutBRONJgivebirthtoaconceptthatosteoclastsplayacriti- calroleintheself-defenseofthejaw(Fig.4).Hence,itsuggests thatBRONJorotherrelatedjawdiseaseisnewlyclassifiedasdrug- relatedosteoclasticdiseaseofthejaw.Weshouldprepareforthe challengesfromsuchnewdiseases.

References

[1]MarxRE. Pamidronate (Aredia) and zoledronate(Zometa) inducedavas- cular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–7.

[2]KimmeDB.Mechanismofaction,pharmacokineticandpharmacodynamicpro- file,andclinicalapplicationsofnitrogen-containingbisphosphonates.JDentRes 2007;86:1022–33.

[3]TaylorKH,MiddlefellLS,MizenKD.Osteonecrosisofthejawsinducebyanti- RANKligandtherapy.BrJOralMaxillofacSurg2010;48:221–313.

[4]AghalooTL,FelsenfeldAL,TetradisS.Osteonecrosisofthejawinapatienton denosumab.JOralMaxillofacSurg2010;68:959–63.

[5]AdvisoryTaskForceonBisphosphonate-RelatedOsteonecrosisoftheJaw.

American Association of Oral and Maxillofacial Surgeons position paper onbisphosphonate-relatedosteonecrosisofthejaws.JOralMaxillofacSurg 2007;65:369–76.

[6]The impact of osteonecrosis of the jaw on osteonecrosis manage- ment: executive summary of a European society on clinical and eco- nomic aspects of osteoporosis and foundation for research on osteo- porosis and other bone diseases working group meeting. Available at http://www.ecceo8.org/mailing/esceo/esceo0530.html.

[7]MavrokokkiT,ChengA,SteinB,etal.Natureandfrequencyofbisphosphonate- associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415–23.

[8] LoJC,O’RyanFS,GordonNP,etal.Predictingriskofosteonecrosisofthe jawwithoralbisphosphonateexposure(PROBE)investigators.Prevalenceof osteonecrosisofthejawinpatientswithoralbisphosphonateexposure.JOral MaxillofacSurg2010;68:243–53.

[9]UradeM,TanakaN,FurusawaK,etal.Nationwidesurveyforbisphosphonate- related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 2011;69:e364–71.

[10]SedghizadehPP,StanleyK,CaligiuriM,etal.Oralbisphosphonateuseandthe prevalenceofosteonecrosisofthejaw:aninstitutionalinquiry.JAmDentAssoc 2009;140:61–6.

[11]Boonyapakorn T, SchirmerI, Reichart PA, et al. Bisphosphonate-induced osteonecrosisofthejaws:prospectivestudy of80 patientswithmultiple myelomaandothermalignancies.OralOncol2008;44:857–69.

[12]RuggieroSL,DodsonTB,AssaelLA,etal.AmericanAssociationofOralandMax- illofacialSurgeonsAmericanAssociationofOralandMaxillofacialSurgeons positionpaperonbisphosphonate-relatedosteonecrosisofthejaws2009 update.JOralMaxillofacSurg2009;67(Suppl.1):2–12.

[13] ArceK,AssaelLA,WeissmanJL,etal.Imagingfindingsinbisphosphonate- relatedosteonecrosisofjaws.JOralMaxillofacSurg2009;67(Suppl.1):75–84.

[14]Kos M, Brusco D, Kuebler J, et al. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonatesadministration.IntJOralMaxillofacSurg2010;39:1097–120.

[15]GanguliA,StewardC,ButlerSL,etal.Bacterialadhesiontobisphosphonate coatedhydroxyapatite.JMaterSciMaterMed2005;16:283–7.

[16] HansenT,KunkelM,WeberA,etal.Osteonecrosisofthejawsinpatients treatedwithbisphosphonates– histomorphologicanalysisincomparisonwith infectedosteoradionecrosis.JOralPatholMed2006;35:155–60.

參考文獻

相關文件

Animal or vegetable fats and oils and their fractiors, boiled, oxidised, dehydrated, sulphurised, blown, polymerised by heat in vacuum or in inert gas or otherwise chemically

Milk and cream, in powder, granule or other solid form, of a fat content, by weight, exceeding 1.5%, not containing added sugar or other sweetening matter.

(c) Draw the graph of as a function of and draw the secant lines whose slopes are the average velocities in part (a) and the tangent line whose slope is the instantaneous velocity

You are given the wavelength and total energy of a light pulse and asked to find the number of photons it

Reading Task 6: Genre Structure and Language Features. • Now let’s look at how language features (e.g. sentence patterns) are connected to the structure

refined generic skills, values education, information literacy, Language across the Curriculum (

Wang, Solving pseudomonotone variational inequalities and pseudocon- vex optimization problems using the projection neural network, IEEE Transactions on Neural Networks 17

volume suppressed mass: (TeV) 2 /M P ∼ 10 −4 eV → mm range can be experimentally tested for any number of extra dimensions - Light U(1) gauge bosons: no derivative couplings. =>